Physician profile
Christopher L Simank
NPI 1346238524
$2,069.65
in general payments reported to CMS, 2019-2025
16 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $107 · 2021: $344 · 2022: $360 · 2023: $306 · 2024: $326 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939 · Entertainment: $32.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.85 |
| Entertainment | $32.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $742.76 | 2019-2025 | Precision 1, Precision7, Dailies Total1 |
| Sun Pharmaceutical Industries INC. | $269.75 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $228.37 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $163.74 | 2022-2025 | Infuse, Vyzulta, Prolensa |
| Johnson & Johnson Vision Care, INC. | $163.66 | 2022-2025 | Acuvue |
| Oyster Point Pharma, INC. | $133.32 | 2022-2024 | Tyrvaya, Ryzumvi |
| Optos, INC. | $109.90 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $52.55 | 2025 | Xdemvy |
| Shire North American Group INC | $45.06 | 2019 | |
| Dompe US, INC. | $43.94 | 2024-2025 | Oxervate |
| Allergan, INC. | $36.71 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $27.04 | 2021 | |
| Harrow Eye, LLC | $22.10 | 2025 | Vevye |
| Quidel Corporation | $13.91 | 2019 | |
| Aerie Pharmaceuticals, INC. | $12.96 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $3.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Simank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.